Pharmaceutical formulation of palbociclib and a preparation method thereof

• US 10,449,195 B2
• Filed: 06/05/2017
• Issued: 10/22/2019
• Est. Priority Date: 03/29/2016
• Status: Active Grant

• Current Assignee: Shenzhen Pharmacin Co., Ltd.
• Original Assignee: Shenzhen Pharmacin Co., Ltd.
• Inventors: Wang, Zeren, Xu, Jun, Qu, Long
• Primary Examiner(s): Pihonak, Sarah
• Application Number:
  US15/613,853
• Publication Number:
  US 20170281631A1
• Time in Patent Office: 869 Days
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: A61K 9/4808 characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

The present invention belongs to the pharmaceutical field, and in particular, it relates to a pharmaceutical formulation of palbociclib and a preparation method thereof. The pharmaceutical formulation comprises palbociclib, an acidic auxiliary material, and optionally a hydrophilic high-molecular weight material, which has better solubility and in vitro dissolution property as compared with the conventional formulation and can be used for enhancing in vivo absorption and bioavailability of palbociclib.

Claims

1. A single amorphous solid dispersion, wherein the single amorphous solid dispersion comprises:

palbociclib or a pharmaceutically acceptable salt thereof;

tartaric acid; and

a hydrophilic high-molecular weight material, wherein a mass ratio of the tartaric acid to the palbociclib or the pharmaceutically acceptable salt thereof ranges from 0.5;

1 to 5;

1, wherein the palbociclib and the tartaric acid are dispersed within the hydrophilic high-molecular weight material; and

wherein the palbociclib and tartaric acid are in an amorphous state.

2. The single amorphous solid dispersion according to claim 1, further comprising a pharmaceutically acceptable inorganic acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, and combinations thereof.

3. The single amorphous solid dispersion according to claim 1, wherein the hydrophilic high-molecular weight material is one or more selected from the group consisting of povidone K30, copovidone VA64, Soluplus, hydroxypropylmethylcellulose E5, hydroxypropylmethylcellulose acetate succinate, hydroxypropyl-β

-cyclodextrin and sulfobutyl ether-β

-cyclodextrin.

4. The single amorphous solid dispersion according claim 1, wherein a mass ratio of the hydrophilic high-molecular weight material to the palbociclib or the pharmaceutically acceptable salt thereof is from 0.1:

1 to 10;

1.

5. The single amorphous solid dispersion according to claim 4, wherein the mass ratio of the hydrophilic high-molecular weight material to the palbociclib or the pharmaceutically acceptable salt thereof is from 1:

1 to 3;

1, and the mass ratio of the tartaric acid to the palbociclib or the pharmaceutically acceptable salt thereof is from 0.5;

1 to 2;

1.

6. A method for preparing the single amorphous solid dispersion according to claim 1, comprising:

mixing the palbociclib or the pharmaceutically acceptable salt thereof with the tartaric acid, adding a solvent for dissolving or dispersing, adding the hydrophilic high-molecular weight material, dissolving or dispersing evenly, and removing the solvent by heating.

7. The method according to claim 6, wherein the concentration of the palbociclib or the pharmaceutically acceptable salt thereof in the solvent is 50 mg/ml or more.

8. The method according to claim 6, wherein the concentration of the palbociclib or the pharmaceutically acceptable salt thereof in the solvent is up to 50 mg/ml.